{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:16:20Z","timestamp":1790802980742,"version":"4.1.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T00:00:00Z","timestamp":1494547200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s00125-017-4301-8","type":"journal-article","created":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T06:58:43Z","timestamp":1494572323000},"page":"1385-1389","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":222,"title":["SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System"],"prefix":"10.1007","volume":"60","author":[{"given":"Gian Paolo","family":"Fadini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta Maria","family":"Bonora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Avogaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,12]]},"reference":[{"key":"4301_CR1","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128","journal-title":"N Engl J Med"},{"key":"4301_CR2","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jcjd.2014.05.006","volume":"38","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ, Perkins BA (2014) Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection? Can J Diabetes 38:356\u2013363","journal-title":"Can J Diabetes"},{"key":"4301_CR3","unstructured":"U.S. Food and Drug Administration (2015) Drug safety communications. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. Available from: \nwww.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM446954.pdf\n\n. Accessed 6 Apr 2017"},{"key":"4301_CR4","unstructured":"European Medicines Agency (2015) Review of diabetes medicines called SGLT2 inhibitors started: risk of diabetic ketoacidosis to be examined. Available from: \nwww.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/SGLT2_inhibitors__20\/Procedure_started\/WC500187926.pdf\n\n. Accessed 6 Apr 2017"},{"key":"4301_CR5","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","volume":"65","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Baldi S, Frascerra S et al (2016) Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65:1190\u20131195","journal-title":"Diabetes"},{"key":"4301_CR6","first-page":"A299","volume":"65","author":"GK Dimitriadis","year":"2016","unstructured":"Dimitriadis GK, Manjunatha R, Harrold C (2016) Latent autoimmune diabetes in an adult initially thought to have type 2 diabetes mellitus, diagnosed after developing diabetic ketoacidosis secondary to the use of sodium glucose co-transporter 2 inhibitors. Diabetes 65:A299","journal-title":"Diabetes"},{"key":"4301_CR7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.clpt.6100258","volume":"82","author":"JS Almenoff","year":"2007","unstructured":"Almenoff JS, Pattishall EN, Gibbs TG et al (2007) Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther 82:157\u2013166","journal-title":"Clin Pharmacol Ther"},{"key":"4301_CR8","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nbt.3623","volume":"34","author":"M Sarangdhar","year":"2016","unstructured":"Sarangdhar M, Tabar S, Schmidt C et al (2016) Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data. Nat Biotechnol 34:697\u2013700","journal-title":"Nat Biotechnol"},{"key":"4301_CR9","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s40264-014-0225-0","volume":"37","author":"KB Hoffman","year":"2014","unstructured":"Hoffman KB, Demakas AR, Dimbil M, Tatonetti NP, Erdman CB (2014) Stimulated reporting: the impact of US Food and Drug Administration-issued alerts on the Adverse Event Reporting System (FAERS). Drug Saf 37:971\u2013980","journal-title":"Drug Saf"},{"key":"4301_CR10","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jdiacomp.2016.06.023","volume":"31","author":"Y Kamata","year":"2017","unstructured":"Kamata Y, Takano K, Kishihara E et al (2017) Distinct clinical characteristics and therapeutic modalities for diabetic ketoacidosis in type 1 and type 2 diabetes mellitus. J Diabetes Complicat 31:468\u2013472","journal-title":"J Diabetes Complicat"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-017-4301-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-017-4301-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-017-4301-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T06:18:02Z","timestamp":1498717082000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-017-4301-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,12]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["4301"],"URL":"https:\/\/doi.org\/10.1007\/s00125-017-4301-8","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,12]]}}}